Difficult to assess are the value to other players (drug Co's.) of any unique strategy improvements. And also in my opinion,
all such ilk offer sure fire shorting glories after an almost accumulated thoughtless posse algorithm selection, as boilerplate cautions such as this always prevail: "Assessment of the clinical benefit of cancer treatments can be highly subjective, influenced by both perspective and context. Such assessments are required in regulatory and policy decision-making, but consistency between jurisdictions is often lacking. Clear and consistent standards for determining when a treatment offers a meaningful benefit, relative to the current standard of care, can help to address issues of equity and transparency in health technology assessment."
Difficult to assess are the value to other players of any unique strategy improvement.
